Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Tumori ; 96(3): 443-7, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20845806

RESUMO

AIMS AND BACKGROUND: The aggressiveness of cancer care near the end of life and the consumption of opioids are potential indicators of quality of care in palliative and end-of-life settings. The purpose of this article is to present a retrospective analysis regarding these themes and the adopted procedures to improve quality of care. METHODS: We evaluated all cancer patients treated and deceased during 2008 and considered those who died and received any antiblastic therapy within 14 and 30 days prior to death. Moreover, we evaluated the annual consumption of pure opioids during 2007 and 2008 in our inpatient clinic. We found that 5% and 9% of all treated patients were still receiving antiblastic treatment near the end of life within respectively 14 and 30 days prior to death (respectively 29.6% and 51.5% of deceased patients). All but 2 patients died from progressive disease, one patient died from acute myocardial infarction during chemotherapy, and one of severe sepsis after chemotherapy for non-Hodgkin lymphoma. As regards the annual consumption of strong opioids, there was a 179% increase in the use of morphine-equivalent doses of oral long-acting opioids (+228% for oxycodone) after the introduction of daily pain measurement through a numerical rating scale. CONCLUSIONS: To reduce the administration of chemotherapy near the end of life, we introduced the palliative prognostic score, to be administered to all advanced cancer patients with performance status of at least 2. To evaluate the effectiveness of analgesics and to reduce the cases of undertreatment of cancer pain, we adopted, in addition to the numerical rating scale, Cleeland's Pain Management Index. We are convinced that attempts to improve the quality of care can be achieved by the collaboration of all health professionals, patients and care givers.


Assuntos
Analgésicos Opioides/uso terapêutico , Benchmarking , Governança Clínica , Oncologia/normas , Neoplasias/complicações , Medição da Dor , Dor/tratamento farmacológico , Cuidados Paliativos/normas , Qualidade da Assistência à Saúde , Assistência Terminal/normas , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/administração & dosagem , Antineoplásicos/uso terapêutico , Benchmarking/tendências , Governança Clínica/tendências , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Dor/etiologia , Medição da Dor/métodos , Cuidados Paliativos/métodos , Equipe de Assistência ao Paciente , Prognóstico , Qualidade da Assistência à Saúde/tendências , Estudos Retrospectivos , Índice de Gravidade de Doença , Assistência Terminal/métodos
2.
Nano Lett ; 5(6): 1107-10, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15943451

RESUMO

We demonstrate the possibility of using carbon nanotubes (CNTs) as potential devices able to improve neural signal transfer while supporting dendrite elongation and cell adhesion. The results strongly suggest that the growth of neuronal circuits on a CNT grid is accompanied by a significant increase in network activity. The increase in the efficacy of neural signal transmission may be related to the specific properties of CNT materials, such as the high electrical conductivity.


Assuntos
Eletroquímica/métodos , Nanotecnologia/métodos , Nanotubos de Carbono/química , Neurônios/metabolismo , Animais , Astrócitos/metabolismo , Adesão Celular , Sobrevivência Celular , Cristalização , Dendritos/metabolismo , Eletrônica , Proteína Glial Fibrilar Ácida/metabolismo , Hipocampo/metabolismo , Humanos , Imuno-Histoquímica , Modelos Químicos , Transdução de Sinais , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA